Global Regulatory News
|
|
- Elizabeth Norton
- 6 years ago
- Views:
Transcription
1 Online Exclusive from PHARMACEUTICAL ENGINEERING THE OFFICIAL TECHNICAL MAGAZINE OF ISPE JANUARY/FEBRUARY 2015, VOL 35, NO 1 Copyright ISPE regulatory compliance Global Regulatory News Asia/Pacific Rim Australia TGA Issues Business Plan The TGA Business Plan , which can be found at: tga.gov.au/publication/tga-businessplan , provides an overview of the organisation s strategic considerations including the mission, key roles and responsibilities, priorities and areas of particular emphasis, and significant changes and challenges. International Efforts Cease to Establish a Joint Therapeutic Products Regulator 1 The Hon. Peter Dutton MP, Minister for Health for Australia, and the Hon. Dr. Jonathan Coleman, Minister of Health for New Zealand, announced their governments agreement to cease efforts to establish a joint therapeutic products regulator, the Australia New Zealand Therapeutic Products Agency (ANZTPA). The decision was made following a comprehensive review of progress and assessment of the costs and benefits to each country of proceeding. While work on ANZTPA will cease, the two countries will continue to cooperate on the regulation of therapeutic products where there are mutual benefits for consumers, businesses and regulators in each country. Chinese FDA and US FDA Sign Cooperation Document 2 On 21 November 2014, Wu Zhen, Vice Minister of China Food and Drug Administration (CFDA) met with the delegation headed by Dr. Margaret Hamburg, Commissioner of the US Food and Drug Administration (FDA). Both sides exchanged opinions on topics of common concerns such as further deepening of China-US cooperation in drug supervision, mutual cooperation and support in relevant international organizations, and the exchange of regulatory staff. After the meeting, Wu Zhen and Margaret Hamburg signed the Implementing Arrangement between the Food and Drug Administration of the Department of Health and Human Services of the United States of America and the China Food and Drug Administration of the People s Republic of China regarding the cooperative mechanism of regulatory staff. Exchange of regulatory staff between the two countries will contribute to ensure food and drug safety for both countries and boosting exchanges and cooperation between both sides in the field of supervision. ICH News from the ICH Steering Committee 3 The Steering Committee (SC) agreed on the key issues relating to the reform of ICH in terms of governance, new membership and funding. ICH remains committed to enhanced communication, transparency and the openness of ICH to all relevant stakeholders. The SC will now proceed with finalizing the Articles of Association and funding model that will allow the ICH parties to carry out their internal consultations, which will pave the way toward establishing ICH as a legal entity as an international association under Swiss law. Membership in the Assembly, which will be the overarching body of the Association, will be established as soon as the legal entity has been set up. TGA Upgrades Website 5 TGA has implemented a new search engine and has improved navigation on the TGA website. All the website content will still be available, but it will now be easier to find. Expert Review of Medicines and Medical Devices Regulation 6 The Australian Government is planning a review of the regulation of medicines and medical devices. The Review will be conducted by a panel of three experts: Emeritus Professor Lloyd Sansom AO, Will Delaat AM, and Professor John Horvath AO. The Review will examine specific aspects of the regulatory framework for medicines and medical devices administered by the Therapeutic Goods Administration with a view to identifying: Areas of unnecessary, duplicative, or ineffective regulation that could be removed or streamlined without undermining the safety or quality of therapeutic goods available in Australia. Opportunities to enhance the regulatory framework so that Australia continues to be well positioned to respond effectively to global trends in the development, manufacture, marketing and regulation of therapeutic goods. PHARMACEUTICAL ENGINEERING JANUARY/FEBRUARY
2 China CFDA Issues the Third Supplement to Chinese Pharmacopeia (2010 Edition) 7 The China Food and Drug Administration (CFDA) has issued the Third Supplement to the Chinese Pharmacopeia (2010 edition) that will go into force as of 1 February The Third Supplement makes improvements in testing technology, impurity control and other aspects. Japan Revision of the Ministerial Ordinance on Standards for Manufacturing Control and Quality Control for Medical Devices and In-Vitro Diagnostics 8 Major points of the amendments to the Ministerial Ordinance on Standards for Manufacturing Control and Quality Control for Medical Devices and In-Vitro Diagnostics include: 1. Harmonizing the 2nd chapter of the ordinance with ISO13485: Describing the additional requirements to ISO13485:2003 in the 3rd chapter of the ordinance Singapore Health Sciences Authority Proposes Subsidiary Legislation for the Transfer of Controls of Pharmaceutical Products to Health Products Act 9 Currently, the legislative controls for pharmaceutical products are covered under different Acts, namely the Medicines Act (Cap. 176) and Poisons Act (Cap. 234). Consolidating the relevant controls under the HPA will provide greater clarity to stakeholders as they would only need to refer to a single legislation. Europe European Union EMA Releases Practical Guidance on Access-to-Documents Requests 10 The European Medicines Agency (EMA) has released a practical guide detailing the process for requesting access to unpublished documents held by the Agency. The guide details in particular: How a request is processed How the documents are provided In which cases access can be refused How a requester can appeal EMA s decision to refuse access to documents EMA Management Board Discusses Next Steps after Judgment of EU Civil Service Tribunal 11 The European Medicines Agency s (EMA) Management Board held a meeting on 27 November 2014 in Rome, Italy to discuss the consequences of the judgment by the European Union Civil Service Tribunal that annulled the appointment of the Agency s Executive Director Guido Rasi. The Management Board chaired by Sir Kent Woods confirmed that Deputy Executive Director Andreas Pott will be in charge of the management and operations of the Agency until the new selection procedure suggested by the European Commission is finalized. The European Commission plans to publish a vacancy announcement for the post of Executive Director shortly. EMA Releases Practical Guidance on Access-to-Documents Requests 12 The European Medicines Agency (EMA) has released a practical guide detailing the process for requesting access to unpublished documents held by the Agency. As foreseen by European Union law and detailed in the EMA s 2010 access-to-documents policy, citizens can have access to documents held by EMA. The guidance can be found at: jsp?curl=pages/news_and_events/ news/2014/11/news_detail_ Conflicts of Interest: Revised EMA Policy Reflects More Balanced Approach 13 The European Medicines Agency (EMA) has published its revised policy on handling declarations of interests for scientific committee members and experts. The revisions reflect a more balanced approach to handling conflicts of interests that aims to effectively restrict the involvement of experts with possible conflicts of interests in the Agency s work while maintaining EMA s ability to access the best available expertise. The revised policy, which was endorsed by the EMA Management Board in March 2014, takes into account input from stakeholders at the Agency s September 2013 public workshop Best expertise vs conflicts of interests: striking the right balance. United Kingdom Professor Sir Michael Rawlins appointed Chair of Medicines and Healthcare Products Regulatory Agency 14 The Medicines and Healthcare Products Regulatory Agency has appointed Professor Sir Michael Rawlins as its new Chair effective 1 December 2014 and his appointment will be for three years. Professor Sir Michael assumes the role from Sir Gordon Duff who announced his intention to step down earlier this year, following his election as Principal of St Hilda s College, Oxford. Professor Sir Michael Rawlins was until recently Chair of the National Institute of Health and Clinical 2 JANUARY/FEBRUARY 2015 PHARMACEUTICAL ENGINEERING
3 Excellence (NICE), a role from which he stood down in He is also currently Chairman of Biobank. North America United States FDA Issues Three Policy Documents on Compounding of Sterile Drugs 15 The FDA has issued three additional policy documents to assist entities that compound sterile human drugs with registering as outsourcing facilities. The policy documents also will assist entities with complying with provisions of the Drug Quality and Security Act (DQSA), which was enacted in November The new guidance documents are: Final guidance on registration of human drug compounding outsourcing facilities under section 503B of the FD&C Act. This final guidance assists compounding facilities that decide to register as outsourcing facilities with the logistics of registering with the FDA, and the process for registering, re-registering, and de-registering. Final guidance on fees for human drug compounding outsourcing facilities under sections 503B and 744K of the FD&C Act. This final guidance provides information about the fees that a facility must pay to register as an outsourcing facility; how facilities can submit payment to the FDA; the consequences of failure to pay fees; and how a facility can qualify as a small business to obtain a reduction in registration fees. The guidance also provides information on fees that may be assessed for reinspection of outsourcing facilities. Revised draft guidance on electronic drug product reporting for human drug compounding outsourcing facilities under section 503B of the FD&C Act. This revised draft guidance provides information about the electronic submission of drug product reports to the FDA for registered outsourcing facilities. Upon initial registration as an outsourcing facility and twice each year, registrants must electronically submit a drug product report to the FDA. This report must identify all drugs compounded by the outsourcing facility during the previous six-month period and provide certain information for each compounded drug. The draft guidance on electronic drug product reporting is available in the Federal Register for public comment for 60 days. FDA Publishes Guidance on Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture 16 This guidance provides recommendations intended to assist in determining which reporting mechanism is appropriate for submission of changes to an approved Biologics License Application (BLA) in accordance with the requirements under Title 21 of the Code of Federal Regulations (CFR) (21 CFR ), including recommendations in connection with the applicability and content of comparability protocols under 21 CFR (e) and labeling changes under 21 CFR (f). This guidance finalizes the draft guidance of the same title dated June 2013 (78 FR 32668, May 31, 2013) and supersedes the guidance entitled, Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture dated July 2001 (66 FR 41247, August 7, 2001). FDA Releases Guidance for Industry: Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection 17 The Food and Drug Administration Safety and Innovation Act added a provision to the Food, Drug, and Cosmetic Act concerning inspections that makes a drug adulterated. This guidance defines the types of actions, inaction, and circumstances that FDA considers to constitute delaying, denying, or limiting inspection, or refusing to permit entry or inspection for the purposes of making a drug adulterated. FDA Updates Information on Postmarket Drug Quality Sampling and Testing Programs 18 Every year, the FDA monitors and tests hundreds of drug products and active pharmaceutical ingredients to help ensure safe, effective and high-quality products are available to consumers. The FDA has posted regarding postmarket drug quality sampling and testing programs to provide product safety and effectiveness test results to health care professionals and consumers. More information can be found on FDA s Drug Quality Sampling and Testing page at FDA Issues Draft Guidance for Industry: The Effect of Section 585 of the FD&C Act on Drug Product Tracing and Wholesale Drug Distributor and Third-Party Logistics Provider Licensing Standards and Requirements: Questions and Answers 19 The FDA is issuing this guidance to assist stakeholders in understanding the effects of section 585 (Uniform National Policy) of the Food Drug and Cosmetic Act, which was added by the Drug Supply Chain Security Act (DSCSA). The DSCSA establishes a Federal system for tracing pre- PHARMACEUTICAL ENGINEERING JANUARY/FEBRUARY
4 scription drug products through the pharmaceutical distribution supply chain. It also requires FDA to establish federal standards for licensing of wholesale drug distributors and third party logistics providers. Section 585 sets forth a uniform national policy preempting states from establishing or continuing in effect certain standards and requirements related to prescription drug product tracing and licensing, wholesale distributors and third-party logistics providers. Guidance on Critical Path Innovation Meetings 20 This draft guidance, which can be found at: loads/drugs/guidancecompliance- RegulatoryInformation/Guidances/ UCM pdf, describes a Critical Path Innovation Meeting (CPIM), a means by which FDA s Center for Drug Evaluation and Research (CDER) and investigators from industry, academia, government, and patient advocacy groups can communicate to improve efficiency and success in drug development. The goals of the CPIM are to discuss a methodology or technology proposed by the meeting requester and for CDER to provide general advice on how this methodology or technology might enhance drug development. The discussions and background information submitted through the CPIM are nonbinding on both FDA and CPIM requesters. FDA Issues Final Rule on Changes to Pregnancy and Lactation Labeling Information for Prescription Drug and Biological Products 21 The US Food and Drug Administration published a final rule that sets standards for how information about using medicines during pregnancy and breastfeeding is presented in the labeling of prescription drugs and biological products. The new content and formatting requirements will provide a more consistent way to include relevant information about the risks and benefits of prescription drugs and biological products used during pregnancy and breastfeeding. FDA s Program Alignment Addresses New Regulatory Challenges References 22 In a blog post, FDA Commissioner Margaret Hamburg outlined challenges facing the FDA and an effort of Program Alignment to meet these challenges. The challenges include an increased breath and complexity of FDA s mandate, the impact of globalization on supply chains, and the rapid scientific innovation and increased biomedical diversity. The Directorates, Centers and the Office of Regulatory Affairs (ORA) have collaborated closely to define the changes needed to align the Agency more strategically and operationally and meet the greater demands placed on it. Each regulatory program has defined new action plans which will provide focus for the year 2015, and in some cases require additional 5 year plans to be developed. For more information, see: gov/fdavoice/index.php/2014/10/ fdas-program-alignment-addressesnew-regulatory-challenges/. FDA Announces Fiscal Year 2015 Regulatory Science Priorities under the Generic Drug User Fee Amendments (GDUFA) of The FDA has published the fiscal year 2015 regulatory science priorities for generic drugs. The FY 2015 research priorities list was prepared based on comments received at the 16 May 2014, public meeting, comments submitted to the public docket, scientific issues raised in citizen petitions, meeting request and controlled correspondence topics, tracked safety issues and discussions within FDA s Center for Drug Evaluation and Research. To comply with this GDUFA requirement, the FDA Office of Generic Drugs developed the following fiscal year 2015 regulatory science priorities for generic drugs: Post-market evaluation of generic drugs Equivalence of complex products Equivalence of locally-acting products Therapeutic equivalence evaluation and standards Computational and analytical tools SUPAC: Manufacturing Equipment Addendum Guidance for Industry 24 This guidance combines and supersedes the following Scale-Up and Post-Approval Changes (SUPAC) guidances for industry: (1) SUPAC-IR/ MR: Immediate Release and Modified Release Solid Oral Dosage Forms, Manufacturing Equipment Addendum, and (2) SUPAC-SS Nonsterile Semisolid Dosage Forms, Manufacturing Equipment Addendum. It removes the lists of manufacturing equipment that were in both guidances and clarifies the types of processes being referenced. A draft guidance, SUPAC: Manufacturing Equipment Addendum, was published on April 1, Comments were received and changes were made to address those comments. References 1. Australian Department of Health, Content/health-mediarel-yr2014- dutton100.htm. 2. China Food and Drug Administration, WS03/CL0757/ html. 3. ICH, press-release-ich-steering-committee-meeting-in-lisbon-november-2014.html. 4. Australian Therapeutic Goods Administration, gov.au/publication/tga-businessplan JANUARY/FEBRUARY 2015 PHARMACEUTICAL ENGINEERING
5 5. Australian Therapeutic Goods Administration, gov.au/upgrade-tga-website. 6. Australian Therapeutic Goods Administration, au/media-release/expert-reviewmedicines-and-medical-devicesregulation#.ve_xcpnf_gg. 7. China Food and Drug Administration, WS03/CL0757/ html. 8. Japanese Ministry of Health, Labour, and Welfare, mhlw.go.jp/english/policy/healthmedical/pharmaceuticals/qms. html. 9. Singapore s Health Sciences Authority, sg/content/hsa/en/news_events/ Press_Releases/2014/hsa-seeksviewsproposedadvert-pharmacylicensing.html. 10. European Medicines Agency, news_and_events/news/2014/11/ news_detail_ European Medicines Agency, news_and_events/news/2014/12/ news_detail_ European Medicines Agency, news_and_events/news/2014/11/ news_detail_ European Medicines Agency, news_and_events/news/2014/11/ news_detail_ British Medicines and Healthcare Products Regulatory Agency Centre/Pressreleases/CON US Food and Drug Administration, ucm pdf. 16. US Food and Drug Administration, Guidances/Blood/ucm htm. 17. US Food and Drug Administration, guidances/ucm pdf. 18. US Food and Drug Administration, ScienceResearch/ucm htm. 19. US Food and Drug Administration, US Food and Drug Administration, developmentapprovalprocess/ druginnovation/ucm htm. 21. US Food and Drug Administration, NewsEvents/Newsroom/PressAnnouncements/ucm htm. 22. US Food and Drug Administration, fdavoice/index.php/2014/10/ fdas-program-alignment-addresses-new-regulatory-challenges/. 23. US Food and Drug Administration, pdf. 24. US Food and Drug Administration, PHARMACEUTICAL ENGINEERING JANUARY/FEBRUARY
6
Guidance for Industry Compounding Animal Drugs from Bulk Drug Substances
#230 Guidance for Industry Compounding Animal Drugs from Bulk Drug Substances DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationCDER Keynote Address. Patrizia Cavazzoni M.D. Deputy Center Director for Operations CDER/FDA. AAM GRx+Biosims Conference September 5, 2018
CDER Keynote Address Patrizia Cavazzoni M.D. Deputy Center Director for Operations CDER/FDA AAM GRx+Biosims Conference September 5, 2018 1 Outline CDER s modernization roadmap Initiatives to facilitate
More informationREGULATORY COMPLIANCE } 19
REGULATORY COMPLIANCE } 19 Reprinted from PHARMACEUTICAL ENGINEERING THE OFFICIAL TECHNICAL MAGAZINE OF ISPE MARCH/APRIL 2015, VOL 35, NO 2 GLOBAL REGULATORY NEWS Copyright ISPE 2015 www.pharmaceuticalengineering.org
More informationSUPPLEMENTAL NOTE ON HOUSE BILL NO. 2055
Brief* SESSION OF 2017 SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2055 As Recommended by House Committee on Health and Human Services HB 2055 would amend the Kansas Pharmacy Act (Act) by deleting, adding, and
More informationKansas Pharmacy Act Amendments; Filling and Refilling Prescriptions; Biological Products; Senate Sub. for HB 2055
Kansas Pharmacy Act Amendments; Filling and Refilling Prescriptions; Biological Products; Senate Sub. for HB 2055 (Act). Senate Sub. for HB 2055 makes several amendments to the Kansas Pharmacy Act The
More information(MPY-201 DRA) - ADVANCE DRA I
(MPY-201 DRA) - ADVANCE DRA I (Indian Legislation) The Drugs and Cosmetics act, 1940 and Rules with emphasis on Good laboratory practices and requirements of premises and equipments (Schedule L-I), Good
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM May 2016 HPFBI CANADA (HEALTH CANADA) No updates NNHPD NHPs Final Monograph for Antiseptic Skin Cleanser Who`s Affected? Companies seeking NPN or DIN for topical antiseptic hand cleansers
More informationGuidance for Industry DRAFT GUIDANCE
Reprinted from FDA s website by EAS Consulting Group, LLC DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product
More informationTestimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC
Testimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC U.S. House of Representatives Energy and Commerce Committee Subcommittee on Health Subcommittee January 30, 2018
More informationCMC Workshop CMC Challenges in Japan. April Bethesda, MD. Yoshihiro Matsuda, Ph.D., PMDA Session 10
CMC Workshop 2015 April 13-15 Bethesda, MD CMC Challenges in Japan Yoshihiro Matsuda, Ph.D., PMDA Session 10 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of
More informationRoles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)
Last revision: 16 September 2010 EMA/537415/2008 Human Medicines Development and Evaluation Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of
More informationChin Koerner Executive Director US Regulatory and Development Policy
Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com
More informationCompounding Animal Drugs From Bulk Drug Substances; Draft Guidance for Industry;
This document is scheduled to be published in the Federal Register on 05/19/2015 and available online at http://federalregister.gov/a/2015-11982, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationDSCSA Implementation: Product Tracing Requirements for Dispensers Compliance Policy (Revised)
DSCSA Implementation: Product Tracing Requirements for Dispensers Compliance Policy (Revised) Guidance for Industry This guidance is for immediate implementation. This guidance is for immediate implementation.
More informationHuman Subject Protection; Acceptance of Data From Clinical Investigations for Medical
This document is scheduled to be published in the Federal Register on 02/21/2018 and available online at https://federalregister.gov/d/2018-03244, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationCATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity
Guidance Agenda: New & Revised Draft Guidances CDER is Planning to Publish During Calendar Year 2015 (See the Good Guidance Practices (GGPs) regulation on this Web page or 21 CFR 10.115 for details about
More informationGCP Convergence Improves Transportability of Medical Device Clinical Data
GCP Convergence Improves Transportability of Medical Device Clinical Data By Harmonization-by-Doing Working Group 4 The safety, performance and effectiveness of medical devices are often evaluated by well-controlled
More informationANDA ANDA APPROVAL
DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 206726 Food and Drug Administration Silver Spring, MD 20993 ANDA APPROVAL Mylan Pharmaceuticals, Inc. 781 Chestnut Ridge Road P.O. Box 4310 Morgantown, WV 26504
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationThe Deemed to be a License Provision of the BPCI Act Questions and Answers Guidance for Industry
The Deemed to be a License Provision of the BPCI Act Questions and Answers Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationEuropean Regulations for Medicines Place and Role of the EDQM and the European Pharmacopoeia
European Regulations for Medicines Place and Role of the EDQM and the European Pharmacopoeia Cathie VIELLE Head of the Ph. Eur. Department, EDQM Structure Council of Europe, European Union and EDQM The
More informationSeptember 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
September 2, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA Draft Guidance: Current Good Manufacturing Practice Interim
More informationWork plan for the GMP/GDP Inspectors Working Group for 2018
30 November 2017 EMA/INS/GMP/504401/2017 Inspections, Human Medicines Pharmacovigilance & Committees Division Work plan for the GMP/GDP Inspectors Working Group for 2018 Chairperson: Brendan Cuddy Adopted:
More informationSec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.
H.R. 2430, FDA Reauthorization Act of 2017 Section 1. Short Title. This Act may be cited as the FDA Reauthorization Act of 2017. Section 2. Table of Contents Table of Contents TITLE I: FEES RELATING TO
More informationCDER 2016 Actions and 2017 Priorities. Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA
CDER 2016 Actions and 2017 Priorities Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA Disclosure My comments today are mine and do not necessarily represent the views of the US
More informationPHARMACEUTICAL COMMITTEE SUMMARY RECORD 60 th meeting, 2 nd May 2006
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals PHARM 529 PHARMACEUTICAL COMMITTEE SUMMARY RECORD 60 th meeting, 2 nd May 2006 OPENING Mr Martin Terberger,
More informationRegulatory requirements and registration process of Generic Drugs in China
13 Regulatory requirements and registration process of Generic Drugs in China Jitendra Kumar Badjatya Deputy Manager-DRA, Montajat Pharmaceutical Company Limited, Dammam, KSA jeetbadjatya@gmail.com ABSTRACT
More informationTitle II Licensure of Wholesale Distributors and 3PL s:
Title II Licensure of Wholesale Distributors and 3PL s: Where does FDA stand, where do states stand, what about VAWD, and what can you do about it? Elizabeth A. Gallenagh, Senior Vice President, Government
More informationDrug Supply Chain Security Act Implementation Track and Trace Issues in 2017
Drug Supply Chain Security Act Implementation Track and Trace Issues in 2017 ILISA BG BERNSTEIN, PharmD, JD Deputy Director, Office of Compliance FDA/CDER Presented at: FDLI DQSA Conference November 15,
More informationThis guidance is for immediate implementation.
Requirements for Transactions with First Responders under Section 582 of the Federal Food, Drug, and Cosmetic Act Compliance Policy Guidance for Industry This guidance is for immediate implementation.
More informationEstablished Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry
Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationCOMMISSION DECISION. of on the creation of a High-Level Expert Group on Sustainable Finance in the context of the Capital Markets Union
EUROPEAN COMMISSION Brussels, 28.10.2016 C(2016) 6912 final COMMISSION DECISION of 28.10.2016 on the creation of a High-Level Expert Group on Sustainable Finance in the context of the Capital Markets Union
More informationFDA s Role in Vaccine Supply
IOM Committee on Review of Priorities of the National Vaccine Plan Stakeholder Workshop #1 24 July 2008 FDA s Role in Vaccine Supply Norman W. Baylor, Ph.D., Director Office of Vaccines Research and Review
More informationINSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND)
INSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND) (The field numbers below correspond to the numbered boxes on the Form FDA 1571) Field 1: NAME OF SPONSOR The sponsor
More informationINSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND)
INSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND) (The field numbers below correspond to the numbered boxes on the Form FDA 1571) Field 1: NAME OF SPONSOR The sponsor
More informationOffice of Pharmaceutical Quality Progress Update
Office of Pharmaceutical Quality Progress Update Michael Kopcha, Ph.D., R.Ph. Director Office of Pharmaceutical Quality CDER/FDA 2017 3 rd PQRI/FDA Conference on Advancing Product Quality March 22-24,
More informationCourse Title ID Duration Basic Premium. Biological Evaluation of Medical Devices: A Risk-Based Approach N mins
Pre-Clinical Basic Level : CMDA Certified Medical Device Associate Biological Evaluation of Medical Devices: A Risk-Based Approach N134 63 mins 186.00 144.00 Introduction to Process Validation N135 75
More informationGuidance for Industry
Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM January 2016 HPFBI CANADA (HEALTH CANADA) NNHPD NHPs Notice to Stakeholders Regarding Site Licensing Update Who s affected? Manufacturers, packagers, labellers, importers, and distributors
More informationPharmaceutical Reference Standards: Overview and Role in Global Harmonization
Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference
More informationDocket No. FDA-2013-D-0114, Draft Guidance Distinguishing Medical Device Recalls From Product Enhancements; Reporting Requirements
One Boston Scientific Place Natick, MA 01760 (508) 652-7400 Tel (508) 652-1898 Fax www.bostonscientific.com May 20, 2013 Divisions of Docket Management (HFA-305) Food and Drug Administration 5630 Fishers
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL GUIDELINE FOR A LICENCE TO MANUFACTURE, IMPORT, EXPORT OR DISTRIBUTE MEDICAL DEVICES & IVDs This guideline is intended to provide recommendations to applicants wishing to submit
More informationANDA ANDA APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring, MD 20993 ANDA 206388 ANDA APPROVAL Teva Pharmaceuticals USA, Inc. 425 Privet Rd. Horsham, PA 19044 Attention: Rich Leone
More informationBill 68, Modernizing Ontario's Municipal Legislation Act, Implications for the City of Toronto
EX21.X REPORT FOR ACTION Bill 68, Modernizing Ontario's Municipal Legislation Act, 2016 - Implications for the City of Toronto Date: January 10, 2016 To: Executive Committee From: City Manager and City
More informationABRIDGED PREQUALIFICATION ASSESSMENT. Prequalification of In Vitro Diagnostics
P r e q u a l i f i c a t i o n T e a m - D i a g n o s t i c s ABRIDGED PREQUALIFICATION ASSESSMENT Prequalification of In Vitro Diagnostics PQDx_173 v3 12 September 2017 (This document version supersedes
More informationDanish Act on Clinical Trials of Medicinal Products 1
This is a translation of an extract of the Danish Act on Clinical Trials of Medicinal Products (Danish title: Lov om kliniske forsøg med lægemidler). Only the Danish version has legal validity. Adopted
More informationRoad map for the PMDA International Vision April 2013 Pharmaceuticals and Medical Devices Agency, Japan 1
Road map for the PMDA International Vision April 2013 Pharmaceuticals and Medical Devices Agency, Japan 1 1. Introduction The Pharmaceuticals and Medical Devices Agency (PMDA), a Japanese Incorporated
More informationLegislation, Transition and Implementation Medicines Control Council & SA Health Products Regulatory Authority. SAAPI Conference April 2016
Legislation, Transition and Implementation Medicines Control Council & SA Health Products Regulatory Authority SAAPI Conference 2016 14 April 2016 Outline Introduction How the MCC works Objectives of Amendment
More informationInterim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry U.S. Department of Health and Human Services Food and Drug
More informationAEO. (Authorized Economic Operator) Challenges of Japan Customs. Customs & Tariff Bureau, Ministry of Finance, Japan
AEO (Authorized Economic Operator) Challenges of Japan Customs Customs & Tariff Bureau, Ministry of Finance, Japan International background The global trading system is vulnerable to terrorist exploitation
More informationThus, let s focus on 35% 30% 25% 20% 15% 10%
International Telecommunication Union ROLES OF REGULATORS CRC, MONGOLIA July 2003 Eun-JuKim Senior Advisor for the Asia & Pacific ITU eun-ju.kim@itu.intint Agenda Trends of regulators: Different scenarios
More informationResearch Professionals Network Workshop Series
Research Professionals Network Workshop Series SO YOU THINK YOU KNOW GCP? Mary-Tara Roth Director, CRRO mtroth@bu.edu Gina Daniels Human Research Quality Manager gdaniels@bu.edu What is [ICH] GCP? an
More informationto protect human health throughout the life-cycle of medicinal products;
ICMRA Communications Strategy: 2018-2020 Introduction The International Coalition of Medicines Regulatory Authorities (ICMRA) is a voluntary, highlevel, strategic coordinating, advocacy and leadership
More informationICH Reflection Paper Further Opportunities for Harmonization of Standards for Generic Drugs 1
Further Opportunities for Harmonization of Standards for Generic Drugs 1 Executive Summary This reflection paper outlines a strategic approach for developing and enhancing ICH guidelines to support the
More informationInterim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act
Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry U.S. Department of Health and Human Services Food and Drug
More informationAuthor Signature: Date: 11 October 2017 The author is signing to confirm the technical content of this document
MELBOURNE CHILDREN S TRIALS CENTRE (MCTC) Guideline document title: Developing, amending and complying with research protocols Version: 2.0 Author: Melbourne Children s Trials Centre (MCTC) Author Signature:
More informationSeptember 12, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
September 12, 2013 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: : Draft Guidance for Industry on Pediatric Study Plans: Content
More informationMedical Device Regulatory Roadmap SAMED Conference 2-3 December 2015
Medical Device Regulatory Roadmap SAMED Conference 2-3 December 2015 Dr J. Gouws Registrar of Medicines Overview Global status on MD and IVDs National status on MD and IVDs Legislation Key player and Responsibilities
More informationWork plan for the GMP/GDP Inspectors Working Group for 2017
13 January 2017 EMA/INS/GMP/584202/2016 Work plan for the GMP/GDP Inspectors Working Group for 2017 Chairperson: David Cockburn Adopted: December 2016 1. Meetings scheduled for 2017 Face-to-face meetings
More informationCurrent Good Manufacturing Practice Requirements for Combination Products
[Federal Register: September 23, 2009 (Volume 74, Number 183)] [Proposed Rules] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr23se09-17] -----------------------------------------------------------------------
More informationA SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN
A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN Version 1 - June 2017 A Short Guide For CT Application 1 2 A Short Guide For CT Application DEFINITIONS Clinical
More informationContents. Regulatory Bodies... 13
Contents UNITED STATES... 3 Regulatory Bodies... 3 Product Classification and Regulatory Control... 3 Application Documents... 3 Quality System Requirements... 4 Product and Manufacturer s License... 4
More informationREGIONAL HEALTH AUTHORITIES ACT
Province of Alberta REGIONAL HEALTH AUTHORITIES ACT Revised Statutes of Alberta 2000 Chapter R-10 Current as of June 17, 2014 Office Consolidation Published by Alberta Queen s Printer Alberta Queen s Printer
More informationU.S. Traceability: the Drug Supply Chain Security Act
U.S. Traceability: the Drug Supply Chain Security Act Connie Jung, RPh, PhD Associate Director for Policy & Communications (Acting) Office of Drug Security, Integrity and Recalls Office of Compliance U.S.
More informationCompliance Trends Paula Katz
Compliance Trends Paula Katz Director, Manufacturing Quality Guidance and Policy Staff Office of Manufacturing Quality Office of Compliance Center for Drug Evaluation and Research India Pharmaceutical
More information2. PMDA provides training program to officials from Thai FDA, Thailand (May 26 to 30)
PMDA Updates June, 2014 Hydrangea macrophylla News 1. Japan Officially Joins PIC/S (May 15 to 16) The Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co operation Scheme (PIC/S) Committee
More informationPublic release of clinical information in drug submissions and medical device applications
Public release of clinical information in drug submissions and medical device applications Health Products and Food Branch March 10, 2017 Health Canada is the federal department responsible for helping
More informationEstablishment of Clinical Trial Infrastructure
Taiwan s Strategy in the Establishment of Clinical Trial Infrastructure Chei-Hsiang Chen, Ph. D. Director, Biotechnology and Pharmaceutical Industries Program Office, Ministry of Economic Affairs, Taiwan
More informationAMENDED Draft Report of the Compounding Workgroup
AMENDED Draft Report of the Compounding Workgroup This report summarizes the actions taken by a workgroup convened by the Board of Pharmacy pursuant to the enactment clause of HB 1035 passed during the
More informationTHE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS
THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS What all developers need to know Alicia Baker Director, Global Regulatory Affairs Strategy, Covance John Carlsen, MHA Vice President,
More informationCOMMENTS FROM EUROPABIO GENERAL COMMENTS
SUBMISSION OF COMMENTS ON DETAILED GUIDANCE FOR THE REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES, NOTIFICATION OF SUBSTANTIAL AMENDMENTS
More informationEXPLANATORY MEMORANDUM ON THE EUROPEAN UNION S COMMON FOREIGN AND SECURITY POLICY
14866/17 EXPLANATORY MEMORANDUM ON THE EUROPEAN UNION S COMMON FOREIGN AND SECURITY POLICY COUNCIL DECISION 2017/.../CFSP of 2017 establishing Permanent Structured Cooperation (PESCO) and determining the
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationBGMA Associate Membership
BGMA Associate Membership Making medicines affordable Promoting Innovation November 2011 GENERICS -THE FACTS Generic medicines meet the same standards of quality, safety and efficacy as originator brands.
More informationGuidance for Industry
Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics Additional copies of this guidance are available from the Office of Communication, Training and Manufacturers Assistance
More informationCOMMISSION DECISION. of
EUROPEAN COMMISSION Brussels, 13.9.2018 C(2018) 5921 final COMMISSION DECISION of 13.9.2018 setting up the group of experts on digital freight transport and logistics: the Digital Transport and Logistics
More informationInnovative regulatory thinking to advance pediatric product development:
Innovative regulatory thinking to advance pediatric product development: Prequalification's efforts to address immediate need as guidance to aid long term development progresses Dr. John Gordon WHO Consultant
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationGuideline on the Regulation of Therapeutic Products in New Zealand
Guideline on the Regulation of Therapeutic Products in New Zealand Part 10: Requirements for information for prescribers and consumers Edition 7.0 March 2017 Section 1: Legislation Section summary This
More informationForeign Affairs, Defence and Trade Select Committee Parliament Wellington. 24 March 2016
Foreign Affairs, Defence and Trade Select Committee Parliament Wellington 24 March 2016 Dear Committee Members, Our apologies for a delayed written submission (attached) on the International treaty examination
More informationMedicines Control Council & update on SA Health Products Regulatory Authority
Medicines Control Council & update on SA Health Products Regulatory Authority South African Pharmaceutical Regulatory Affairs Association (SAPRAA) 08 April 2016 Outline Introduction Policy & Legislative
More informationA Proposed Framework for a Waste-Free Ontario Ministry of the Environment and Climate Change Technical Briefing
A Proposed Framework for a Waste-Free Ontario Ministry of the Environment and Climate Change Technical Briefing Fall 2015 Purpose Overview: Background Proposed Legislation: Waste-Free Ontario Act, including:
More informationCHAPTER THE PHARMA LEGAL HANDBOOK SOUTH AFRICA
CHAPTER THE PHARMA LEGAL HANDBOOK SOUTH AFRICA THE PHARMA LEGAL HANDBOOK ANSWERS ESSENTIAL QUESTIONS ABOUT THE LEGAL AND REGULATORY ENVIRONMENT FOR PHARMACEUTICALS IN SOUTH AFRICA. IT IS A MUST-HAVE FOR
More informationStudy & Comparison of Drug Approval Process for Different Countries in Relation to Authorisation Agency & Clinical Trials
ISSN 0976 3333 Available Online at www.ijpba.info International Journal of Pharmaceutical & Biological Archives 2017; 8(6): 25-30 REVIEW ARTICLE Study & Comparison of Drug Approval Process for Different
More informationAN INSIGHT ON ORPHAN DRUG DEVELOPMENT STRATEGY IN US AND EUROPE
ISSN: 2230-7346 Dilip Maheshwari, et al. / JGTPS / 6(1)-(2015) 2322 2327 (Review Article) Journal of Global Trends in Pharmaceutical Sciences Journal home page: www.jgtps.com AN INSIGHT ON ORPHAN DRUG
More informationCharter of the Financial Stability Board 1
June 2012 Having regard to: Charter of the Financial Stability Board 1 (1) the initial mandate given to the Financial Stability Forum by the Finance Ministers and Central Bank Governors of the Group of
More informationFDA Update on Compounding
FDA Update on Compounding Julie Dohm, JD, PhD Senior Science Advisor for Compounding, Center for Drug Evaluation and Research; Agency Lead on Compounding, FDA Compounding A Snapshot Compounded drugs: Are
More informationThe European Commission proposes new rules for medical devices
for medical devices On 26 September 2012 the European ( ) presented its proposal to the European Parliament and the Council regarding two new regulations on medical devices. The Parliament and the Council
More informationDrug Products, Labeling, and Packaging
442 Pharmaceutical Industry: Drug Products, Labeling, and Packaging Positions Drug Products, Labeling, and Packaging Ready-to-Administer Packaging for Hazardous Drug Products Intended for Home Use (1711)
More informationBriefing for the Minister of Civil Defence
Briefing for the Minister of Civil Defence Resilient New Zealand Contents 3 Foreword 5 Sector Overview 6 Strategic and Legislative Framework 7 Minister s Role 9 The ministry s Role 10 Key Issues and Themes
More informationKorea GMP & DMF. April Korea Pharmaceutical Traders Association Deputy director Oh Hyun, Kwon
Korea GMP & DMF April. 2015 Korea Pharmaceutical Traders Association Deputy director Oh Hyun, Kwon Contents 1. KPTA 2. Pharmaceutical industry 3. KGMP 4. KDMF KPTA KPTA Purpose ㅇ Trade promotion of pharmaceuticals,
More informationMEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155
MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part
More informationSample Regulatory/Adjudicative Agency Mandate and Roles Document. [Agency name] Mandate and Roles Document
(This sample document has been developed by the Agency Governance Secretariat. It is intended to be used for informational purposes only and is not a Government of Alberta standard document or template.
More informationMandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT)
6 October 2016 EMA/CVMP/ADVENT/630299/2014 Rev.2 Committee for Medicinal Products for Veterinary Use (CVMP) Mandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel
More informationFunctioning of the PRAC
Functioning of the PRAC Sixth Stakeholders forum on the implementation of the new Pharmacovigilance legislation, November 8 th 2012 Presented by: Almath Spooner Vice Chair, Pharmacovigilance Risk Assessment
More informationA Summary of the Government of British Columbia s Crown Agency Accountability System
A Summary of the Government of British Columbia s Crown Agency Accountability System March, 2005 Crown Agencies Secretariat Government of British Columbia Contact us at: (250) 952-0760 www.gov.bc.ca/cas/
More informationJoint Report: Changes to the Public Finance Act and State Sector Act to accommodate organisational forms other than the department
16 December 2011 ST-2-2 Joint Report: Changes to the Public Finance Act and State Sector Act to accommodate organisational forms other than the department Executive Summary The Better Public Services Advisory
More informationInternational Generic Drug Regulators Programme (IGDRP) Information Sharing Pilot
15 January 2015 EMA/789664/2014 International Generic Drug Regulators Programme (IGDRP) Information Sharing Pilot Information package on Participation in the Information Sharing Pilot for the Evaluation
More informationEFFECTIVE PROCESS VALIDATION NUSAGE PharmEng Pharmaceutical and Biotechnology Training Program Copyright 2014 NUSAGE-PharmEng.
EFFECTIVE PROCESS VALIDATION NUSAGE PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry EFFECTIVE PROCESS VALIDATION Objective
More informationGUIDANCE ON THE GMP CLEARANCE OF OVERSEAS MEDICINE MANUFACTURERS
GUIDANCE ON THE GMP CLEARANCE OF OVERSEAS MEDICINE MANUFACTURERS 16 th Edition March 2008 www.tga.gov.au/manuf/gmpsom.htm Page 1 of 18 Table of Contents Introduction... 3 International Arrangements...
More information